English

Choose language

Back

  • Deutsch

  • ελληνική

  • English

  • Español

  • Français

  • Polski

  • Português

  • Русский

  • Українська


English

How do you prefer to top up your account?

* We don't charge any commission for making deposits into your account

Amgen Stock: 10% Yield Potential with New Drug Release Opportunity

Company Name: Amgen, Inc.
Ticker: AMGN
Current Price: $240.49
Target Price: $265.00
Projected Yield: 10.20%
Time Line: Until October 13, 2020
Risk: Average

About Amgen, Inc.

A US based biopharma giant, Amgen is one of the world's largest independent companies in its industry. The company focuses on producing biological products in neurology, oncology, hematology, and other clinical areas.

What's the Idea?

Capitalize on the stock which may rise with increased sales of new products and the release of the stage 3 clinical trials results for a number of drugs.


Buy Amgen Shares >>


Why Trade Amgen Inc.?

Reason 1: Release of Stage 3 Clinical Trials Results Coming Soon

The company has 6 new drugs that are under stage 3 clinical trials, while 10 existing drugs are undergoing additional research aimed at expanding the scope of their application. Amgen's quarterly report mentioned the results were expected in the second six months of 2020, which might push the AMGN shares higher.

Reason 2: Impressive Outlook for the Company's New Drugs

The company reported an increase in sales earnings for the following new drugs: Otezla, MVASI, KANJINTI, EVENITY, and Repatha. These drugs increase the company's presence in the oncology and neurology domains. The rise of the sales earnings of these drugs may also be supported with the expansion of their application. For this, additional studies for these drugs being under stage 3 of the clinical trials are being carried out.

Reason 3: Buyback Program and Dividend Yield

An additional growth driver is the buyback program, for which the company is planning to allocate $4.90 billion more. AMGN shares can also be attractive for dividend investors, with a dividend yield of 2.63%.

How to Use the Investment Idea

  1. Buy Amgen shares at the current price.
  2. Allocate no more than 3% to 4% of your midterm transaction budget.
  3. Sell the stock when the price is at $265 per share.

How to Buy Amgen, Inc, Shares?

If you don't have an investment account yet, open it now: this can be done online, in just 10 minutes. All you need to do is fill out a short form and verify your account.

After opening an account, you can buy shares in either of the following ways:

Freedom24 Online Store: This is the easiest way to do it. Add the number of shares you want to buy to the cart and pay by credit card. Once the transaction is processed, the purchased shares will appear on your investment account.

Freedom24 Web Platform: In the Web Terminal section, type AMGN.US (Amgen, Inc. ticker in the NASDAQ) in the search box, and select Amgen Inc. in the results. Open a secure session in the trading window on the right, select the number of shares you want to buy, and click Buy.

Freedom24 iPhone or Android App: Go to the Price screen and tab the search icon in the top right corner. In the search dialog that shows up, type AMGN.US (Amgen, Inc. ticker in the NASDAQ) and select Amgen Inc in the search results. You will then see Amgen Inc. stock in the market watch; tap it and go to the Order tab in the dialog that shows up. Specify the number of shares you want to buy and click Buy.

Buy Amgen Stock: Don't Miss a Chance to Earn with New Drugs Release!


Buy Amgen Shares >>



*Additional information is available upon request. Investment in securities and other financial instruments always involves risks of capital loss. The Client should make himself aware at his own accord, including to familiarize himself with Risk Disclosure Notice. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Commissions, fees or other charges can diminish financial returns. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and do not constitute an investment advice service. The recipient of this report must make their own independent decisions regarding any securities or financial instruments mentioned herein. Information has been obtained from sources believed to be reliable by Freedom Finance Cyprus Ltd or its affiliates and/or subsidiaries (collectively Freedom Finance). Freedom Finance do not warrant its completeness or accuracy except with respect to any disclosures relative to the Freedom Finance and/or its affiliates and the analyst’s involvement with the issuer that is the subject of the research. All pricing is indicative as of the close of market for the securities discussed, unless otherwise stated.